Low-dose oral minoxidil for children: an international consensus on who, how much and how to monitor

Design

International modified Delphi consensus, three rounds

Population

49 experts from 9 countries, each having treated more than 10 children with oral minoxidil

Primary outcome

Consensus (70% or more agreement) on indications, dosing and monitoring

Effect

84 of 127 statements agreed; supported for ages 4 to under 12 with weight-band dosing

A modified Delphi process published in JAMA Dermatology (30 September 2026) brought together 49 clinicians from nine countries, each of whom had treated more than ten children with low-dose oral minoxidil. Over three rounds they agreed 84 of 127 statements on its use under the age of 12.

The panel supported it from age 4 to under 12 for hair follicle miniaturisation and hair cycle disorders, with full agreement, and for hair shaft disorders, with 84% agreement, and as an adjunct in some scarring alopecias. Reasons to prefer it over topical minoxidil included poor tolerance, difficulty applying it, diffuse loss and the risk to household pets. Dosing by weight band, aligned to tablet sizes, reached consensus: 0.25 to 0.625 mg under 20 kg, 1.25 mg from 20 to 40 kg, and 1.875 mg above 40 kg, or 0.01 to 0.02 mg/kg/day. Pericardial effusion and phaeochromocytoma were contraindications. Routine baseline tests and blood pressure checks were not considered necessary in low-risk children.

This is expert opinion, not trial evidence, and the use remains off-label. Its value is that it replaces improvisation with a shared starting point. Indian clinicians will need to split adult tablets, as paediatric strengths are not generally available.

• Consider low-dose oral minoxidil for children aged 4 to under 12 with non-scarring hair loss when topical treatment fails or is not tolerated.
• Start by weight band: 0.25 to 0.625 mg under 20 kg, 1.25 mg at 20 to 40 kg, 1.875 mg above 40 kg.
• Do not use it in a child with pericardial effusion or phaeochromocytoma.
• Review response every 3 to 6 months, and warn families about generalised hair growth.
• Explain that this is off-label use supported by expert agreement, not trials.

Why it matters

Use in children has grown ahead of any guidance, and this gives a defensible standard to work from.

Don't overread it

A Delphi consensus records what experts agree on; it does not show efficacy or safety in children.

The statistics, in plain English

In a Delphi process, a statement passes when at least 70% of panellists agree. A 100% figure means universal agreement among these experts, not certainty of benefit, and the panel was drawn from clinicians already using the drug, who are more likely to favour it.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.